SCHEMBL4461372

SCHEMBL4461372

COc1cc(Oc2ccc(-c3c[nH]c(COc4ccccc4)n3)cc2)cc(OC)c1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 10/20 0.47
KIT P10721 3/20 0.43
KDR P35968 3/20 0.43
MAPT P10636 3/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MCL1 Q07820 2/20 0.40
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
TUBB2A Q13885 1/20 0.40
TUBB8 Q3ZCM7 1/20 0.40
TUBA3E Q6PEY2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4455245 0.87 NPC1 (0.50) PDGFRBMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL4686964 0.86 MCL1 (0.46) MAPTNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL4460441 0.82 MCL1 (0.42) MAPTNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL4460360 0.81 LTA4H (0.47) NPC1RAB9ASMN1; SMN2MCL1TSHR
SCHEMBL4456543 0.81 MCL1 (0.54) MAPTNPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL4464283 0.81 HTT (0.45) MAPTNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL4457400 0.81 MCL1 (0.41) MAPTNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL4460188 0.80 NPC1 (0.45) MAPTNPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL3270671 0.80 MAOA (0.46) MAPTNPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL4456749 0.80 PRMT5 (0.43) NPC1RAB9ASMN1; SMN2MCL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US disclosed
EP-1638943-B1 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOD CONSEILS RECH APPLIC (FR) 2008-08-06 EP disclosed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments MIF, MCL1, PPIP5K2 PDGFRB 2120/4885KIT 82/4885KDR 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.